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conservative disutility approach of new treatments or at least a
sensitivity analysis.
Thirdly, although the authors used non-invasive assessment
for the staging of ﬁbrosis, they assumed a perfect sensitivity
and speciﬁcity of this approach, which of course is not clinically
plausible [3]. The authors should have incorporated evidence
on the accuracy of the non-invasive test outcomes in their
Markov model and the cost and health implications of each
possible diagnosis: true positive, false positive, false negative,
and true negative.
Fourthly, in terms of life expectancy, the actual difference
between oral therapies for all vs. oral therapy after staging is
1.8 months over 30 years. This marginal difference is at the
expense of treating 17% more patients and is not sufﬁciently
discussed.
We recently completed a cost-effectiveness analysis of non-
invasive tests in informing treatment decisions in patients with
hepatitis C, taking into account the relative sensitivities and spec-
iﬁcities of a wide range of non-invasive ﬁbrosis tests [4]. We were
able to identify a price threshold above which the treat-all
strategy with new treatments is not cost-effective.
As more treatment options become available for HCV, cost-
effectiveness models will become increasingly important in
informing public policy. In order for such models to stand up to
the occasion, we need to get the baseline data right.
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1 patients lead to better clinical and cost outcomesTo the Editor:
We appreciate the input from Tshochatzis et al. in their letter
to the editor about our recently published article [1]. One of the
issues raised has to do with differences in health-related quality
of life (HRQL) related to the stage of ﬁbrosis. Although there is
evidence to suggest that patients with advanced liver disease
have more impairment of HRQL, there is absolutely no credible
evidence to suggest that HRQL impairment is different between
earlier histologic stages of ﬁbrosis [2,3]. On the other hand, we
do agree that when patients have cirrhosis, especially those with
decompensated cirrhosis, their HRQL is signiﬁcantly more
impaired and this was considered in our analysis. As for the dis-
utility of oral regimen, we used actual data obtained from
patients who were treated in clinical trials [4] and did conduct
sensitivity analysis (the online supplementary document pro-Journal of Hepatology 2
nder CC BY-NC-ND license.vides additional details of sensitivity analyses). Therefore, we
believe that our HRQL assumptions for our economic analysis
were correct.
We also understand that our analysis was performed using
efﬁcacy data for all oral regimens from abstracts presented in
international meetings. At the time, this was all the data that
was available. Nevertheless, fully published data from all oral
regimens suggest even higher SVR-12 rates than what we consid-
ered in our model [5,6]. In fact, we believe that our study may
have actually underestimated the cost effectiveness of all oral
regimens which should further strengthen our conclusions.
As far as the staging of liver disease by Fibroscan is con-
cerned, our initial analysis was performed using the ‘‘gold stan-
dard’’ for staging which is liver biopsy. In fact, this approach
yielded very similar results to those of Fibroscan. It is also impor-
tant to note that while Fibroscan is widely used in Europe,
despite FDA approval, Fibroscan is still not widely used or avail-
able in the United States. Part of the problem is large scale vali-014 vol. 61 j 449–455
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dation data using Fibroscan in population with high prevalence
of visceral obesity is lacking and this may affect the performance
of this technology. Nevertheless, our sensitivity analysis showed
that even when the cost of staging (Fibroscan or liver biopsy)
was free and with perfect sensitivity and speciﬁcity, treating all
with an oral regimen remained cost-effective by conservative
standards (less than $50,000/QALY).
It is true that the mean improvement in life expectancy from
treating all for oral therapy is 1.8 months from treating an extra
17%. It would be wrong, however, to characterize that as ‘‘mar-
ginal’’ since that improvement is not spread evenly over the
whole population but is gained entirely in the population at risk
of progression to advanced liver disease. Thus, about 10% of these
extra people treated are prevented from advanced liver disease
and gain over 8 years of life.
Finally, we have used an exhaustive approach to obtain all the
data for the model, including extensive review of the literature,
previously published models, and expert reviews of our assump-
tions. We believe that the assumptions used in our models are
quite robust and our conclusions remain valid.
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